Skip to main content

Healthy Subjects (HS)

6
Pipeline Programs
4
Companies
8
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
6
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 6 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Sunshine Biopharma
Sunshine BiopharmaQC - Varennes
4 programs
4
626Phase 11 trial
627Phase 12 trials
SSS17Phase 11 trial
[14C]SSS17Phase 11 trial
Active Trials
NCT06674525Recruiting50Est. Oct 2025
NCT07507513Not Yet Recruiting288Est. Dec 2029
NCT07065136Not Yet Recruiting108Est. Sep 2026
+2 more trials
Otsuka
OtsukaJapan - Tokushima
1 program
1
SibeprenlimabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT07105124Completed24Est. Feb 2023
Wockhardt
WockhardtNJ - Parsippany
1 program
1
zidebactam administered as a 1gPhase 11 trial
Active Trials
NCT07247942Completed8Est. Jan 2019
GE HealthCare
1 program
DaTSCAN™ IoflupanePHASE_11 trial
Active Trials
NCT04564092Completed9Est. Sep 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Sunshine Biopharma627
Sunshine Biopharma627
Sunshine Biopharma[14C]SSS17
Sunshine BiopharmaSSS17
Sunshine Biopharma626
OtsukaSibeprenlimab
GE HealthCareDaTSCAN™ Ioflupane
Wockhardtzidebactam administered as a 1g

Clinical Trials (8)

Total enrollment: 529 patients across 8 trials

NCT07507513Sunshine Biopharma627

The Purpose of This Study is to Evaluate the Efficacy and Safety of 627 in the Treatment of UC

Start: Mar 2026Est. completion: Dec 2029288 patients
Phase 2Not Yet Recruiting
NCT07065136Sunshine Biopharma627

Evaluation of 627 in Healthy Adult Subjects

Start: Jul 2025Est. completion: Sep 2026108 patients
Phase 1Not Yet Recruiting
NCT07025915Sunshine Biopharma[14C]SSS17

A Phase 1 Mass Balance Study of [¹⁴C]SSS17 in Healthy Chinese Males

Start: Jun 2025Est. completion: Jul 20256 patients
Phase 1Not Yet Recruiting
NCT07024888Sunshine BiopharmaSSS17

A Study Evaluating the Food Effect on the Pharmacokinetics of SSS17 Capsules in Chinese Healthy Subjects

Start: Mar 2025Est. completion: May 202536 patients
Phase 1Completed
NCT06674525Sunshine Biopharma626

Evaluation of 626 in Healthy Adult Subjects

Start: Dec 2024Est. completion: Oct 202550 patients
Phase 1Recruiting
NCT07105124OtsukaSibeprenlimab

Safety and Tolerability, and PK of Sibeprenlimab in Chinese Healthy Subject

Start: Oct 2022Est. completion: Feb 202324 patients
Phase 1Completed
NCT04564092GE HealthCareDaTSCAN™ Ioflupane

A Study to Evaluate the Safety, Biodistribution, Internal Radiation Dosimetry, and Effective Dose of DaTSCAN™ Ioflupane (123I) Injection in Chinese Healthy Volunteers.

Start: May 2021Est. completion: Sep 20219 patients
Phase 1Completed
NCT07247942Wockhardtzidebactam administered as a 1g

Study of the Metabolism and Excretion of Zidebactam (WCK 5107) Following a Single Intravenous Infusion.

Start: Dec 2017Est. completion: Jan 20198 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 529 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.